To evaluate whether the proteasome and/or lysosome pathways are involved in the downregulation of ATGL protein levels in hepatic steatosis, we treated cultured hepatocytes with the proteasome-specific inhibitor MG132 and the lysosomal inhibitor ammonium chloride (NH4Cl), respectively. The gene discussed is PNPLA2; the disease is fatty liver disease.